Blog
RSS FeedPosted by Michael Wonder on 10 Apr 2018
Feds broaden the definition of ‘pharmacy’ in a bid to level playing field for startup
6 April 2018 - Across the US, upstart pharmacies are turning the prescription drug business on its head, offering digitally ...
Posted by Michael Wonder on 10 Apr 2018
Innovative drugs need a new regulatory approach
10 April 2018 - Innovative drugs help people enjoy longer, healthier, more productive lives. They also allow our health-care systems ...
Posted by Michael Wonder on 07 Apr 2018
New drugs: patient hope or harm?
26 March 2018 - Debate on whether new drugs are too expensive for the NHS continues to rage, and contradictory ...
Posted by Michael Wonder on 08 Mar 2018
Balancing safety and innovation for cell-based regenerative medicine
8 March 2018 - Regenerative medicine is a field that involves replacing, engineering, or regenerating human cells, tissues, or organs to ...
Posted by Michael Wonder on 13 Feb 2018
Statement from FDA Commissioner Scott Gottlieb on Administration’s request for new FDA funding to promote innovation and broaden patient access through competition
13 February 2018 - Additional resources will help advance initiatives to support novel medical technology and public health priorities such as ...
Posted by Michael Wonder on 06 Feb 2018
AusBiotech says plan to disadvantage life sciences innovation
6 February 2018 - Response to Innovation and Science Australia 2030 plan. ...
Posted by Michael Wonder on 31 Jan 2018
Industry needs clarity to invest in Australia
31 January 2018 - Medicines Australia welcomes the release of the 2030 plan by Innovation and Science Australia but seeks ...
Posted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 09 Jan 2018
How Allergan continues to make drug prices insane
9 January 2018 - The company kept a promise to limit increases to the single digits. But it didn't stop abusing ...
Posted by Michael Wonder on 09 Jan 2018
Reflections on a landmark year for medical product innovation and public health advances and looking ahead to policy in 2018
9 January 2018 - As we look ahead to 2018, I’d like to take a moment to reflect on an ...
Posted by Michael Wonder on 14 Dec 2017
New steps to facilitate beneficial medical device innovation
14 December 2017 - In recent days, the FDA has committed to several new policies that will modernise the agency’s approach ...
Posted by Michael Wonder on 14 Dec 2017
Bumper crop of new drugs fails to lift big pharma R&D returns
14 December 2017 - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice ...
Posted by Michael Wonder on 08 Dec 2017
Remarks from FDA Commissioner as prepared for oral testimony before the U.S. Senate Committee on Health, Education, Labor & Pensions Hearing, “Implementation of the 21st Century Cures Act: Progress and the Path Forward for Medical Innovation
7 December 2017 - FDA Commissioner Gottlieb provides testimony before the U.S. Senate HELP Committee on the agency’s implementation of the ...
Posted by Michael Wonder on 08 Dec 2017
Statement from FDA Commissioner on advancing new digital health policies to encourage innovation, bring efficiency and modernisation to regulation
7 December 2017 - Today we’re announcing three new, significant policy documents to advance the FDA’s approach to the development ...
Posted by Michael Wonder on 04 Dec 2017
Brand name drug sales soar in Canada, while R&D sags
1 December 2017 - Patented drug industry disputes it's failing to invest enough into research and development. ...